ArticleAutoimmune diseases2010
Pathogenic and Epiphenomenal Anti-DNA Antibodies in SLE.
Article in Autoimmune diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Advances and pitfalls in anti-double-stranded DNA autoantibody detection and interpretation.World journal of biological chemistry · 2026Review
- The Anti-DNA Antibodies: Their Specificities for Unique DNA Structures and Their Unresolved Clinical Impact-A System Criticism and a Hypothesis.Frontiers in immunology · 2021Review
- Serological comparison of systemic lupus erythematosus with neuropsychiatric lupus using synthetic nucleic acid antigens.Journal of translational autoimmunity · 2020Article
- [Acute unilateral non-traumatic enophthalmus].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019Article
- Dihydropyridine Fluorophores Allow for Specific Detection of Human Antibodies in Serum.ACS omega · 2018Article
- Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus.Molecular medicine (Cambridge, Mass.) · 2018Article
- Autoantibody Profiling in Lupus Patients using Synthetic Nucleic Acids.Scientific reports · 2018Article
- Detection of autoimmune antibodies in localized scleroderma by synthetic oligonucleotide antigens.PloS one · 2018Article
- Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus.Scientific reports · 2017Article
- CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Single-Molecule Interactions of a Monoclonal Anti-DNA Antibody with DNA.BioNanoScience · 2017Article
- Synthetic oligonucleotide antigens modified with locked nucleic acids detect disease specific antibodies.Scientific reports · 2016Article
- In-Cell RNA Hydrolysis Assay: A Method for the Determination of the RNase Activity of Potential RNases.Molecular biotechnology · 2015Article
- The effect of polyamines on the binding of anti-DNA antibodies from patients with SLE and normal human subjects.Clinical immunology (Orlando, Fla.) · 2014Article
- Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations.Current genomics · 2014Article
- The constant region affects antigen binding of antibodies to DNA by altering secondary structure.Molecular immunology · 2013Article
- Deoxyribonuclease activity of polyclonal IgGs: a putative serological marker in patients with spondyloarthritides.Immunologic research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discoveries of natural and the development of manufactured highly efficient catalytic antibodies (abzymes) opens the door to many practical applications. One of the most fascinating is the use of such antibodies in human therapy and prevention (vaccination), of cancer, AIDS, autoimmune diseases. A special entity of naturally occurring DNA hydrolytic anti-DNA antibodies is emerging within past decades linked to autoimmune and lymphoproliferative disorders, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), Sjogren Syndrome (SS), B - Chronic lymphocytic leucosis (B-CLL), and Multiple Myeloma (MM). The origin of the antibodies is unknown. The underlying mechanisms of these activities are suggested to be penetration into the living cells and translocation in the nucleus, with recognition of the specific binding sites at particular (ss or ds) DNA. There are controversies in the literature whether hydrolysis is a sequence-specific event. The interplay between anti-DNA antibodies and DNA is not yet elucidated. This molecular "twist" also suggests that anti-DNA antibodies with DNA hydrolytic capacity could be the organism's immune response to a microbial attack, with microbial DNA, or specific genes within microbial DNA sequence, as a target for neutralization. The catalytic antibody-based approach can become a key tool in selective chemotherapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.